January 17th 2025
Experts stress that persons wanting to donate blood should not stop any medications they are on, with some deferrals being permanent and others temporary.
Second Biosimilar Approved to Treat Neutropenia
July 25th 2018A second biosimilar to Amgen’s Neupogen, which treats neutropenia, has been approved in the United States. The FDA approved Pfizer’s filgrastim-aafi, which will be sold under the brand name Nivestym. Zarxio (filgrastim-sndz) was the first filgrastim biosimilar approved by the FDA in 2015.
Read More
First Targeted Therapy Approved for R/R AML With IDH1 Mutation
July 22nd 2018The FDA approved the first targeted therapy for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In addition, FDA also approved a companion diagnostic to be used to detect the specific mutations in the IDH1 gene.
Read More
Screening Tool Could Predict Risk of Developing AML Years Before Disease Onset
July 16th 2018Acute myeloid leukemia can often appear suddenly in patients, without any detectable early symptoms. However, new research has identified the origins of AML, which can be detectable more than 5 years before the disease develops.
Read More